Valore202020212022202320242025TTMSpese di vendita, generali e amministrative10.47 B9.63 B10.04 B10.5 B10.82 B10.73 B10.73 BRicerca e sviluppo13.56 B12.24 B13.55 B30.53 B17.94 B15.79 B15.79 BReddito operativo4.29 B10.64 B14.1 B-437 M17.47 B18.36 B17.74 BProventi non operativi, Totale1.14 B2.69 B-2.3 B27 M845 M484 M484 MOneri finanziari, al netto degli interessi capitalizzati831 M806 M962 M1.15 B1.27 B1.36 B1.36 BProventi non operativi, esclusi gli oneri finanziari-578 M545 M-1.76 B-653 M-450 M-722 M-722 MEntrate/uscite straordinarie886 M1.34 B-1.5 B-466 M24 M-151 M-151 MUtile al lordo delle imposte8.79 B13.88 B16.44 B1.89 B19.94 B21.07 B21.07 BQuota di utile———————Imposte1.71 B1.52 B1.92 B1.51 B2.8 B2.8 B2.8 BInteressi di minoranza15 M16 M7 M12 M16 M9 M9 MAltri proventi/oneri al netto delle imposte49 M-805 M-1.3 B-355 M-510 M-511 M-511 MUtile netto al lordo delle attività cessate7.07 B12.34 B13.81 B-342 M17.12 B18.25 B18.25 BAttività cessate—707 M707 M707 M———Utile netto7.07 B13.05 B14.52 B365 M17.12 B18.25 B18.25 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari7.07 B13.05 B14.52 B365 M17.12 B18.25 B18.25 BUtile base per azione (EPS base)2.795.165.730.146.767.37.3Utile diluito per azione (EPS diluito)2.785.145.710.146.747.287.28Numero medio di azioni ordinarie in circolazione2.53 B2.53 B2.53 B2.54 B2.53 B2.5 B10.03 BAzioni diluite in circolazione2.54 B2.54 B2.54 B2.55 B2.54 B2.51 B10.05 BEBITDA7.91 B13.85 B18 B3.44 B21.97 B24.2 B23.58 BEBIT4.29 B10.64 B14.1 B-437 M17.47 B18.36 B17.74 BCosto del fatturato15.48 B13.63 B17.41 B16.13 B15.19 B16.38 B16.38 BAltri costi del venduto———————Ammortamento e svalutazione (liquidità)3.63 B3.21 B3.91 B3.87 B4.5 B5.84 B5.84 B
Merck & Company Inc (new)
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products.
The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000.
In 1891, Merck & Co. was established as the American affiliate of Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck".